Related Experiment Videos
Effects of recombinant human megakaryocyte growth and development factor on platelet activation
G Montrucchio1, M F Brizzi, G Calosso
1Dipartimento di Fisiopatologia Clinica, Università di Torino, Italy.
Abstract:
The c-Mpl receptor for thrombopoietin and its recombinant related protein, the megakaryocyte growth and development factor (MGDF), is also expressed on circulating platelets. In the present study we evaluated the effect of MGDF on platelet aggregation in platelet-rich plasma (PRP) and in whole blood. The results obtained indicate that MGDF by itself did not affect platelet aggregation. However, when added before other agonists such as adenosine diphosphates (ADP), epinephrine (EPI), and thrombin (THR), it rendered platelets more sensitive. This "priming" effect of MGDF was dependent on the dose and on the time of platelet preincubation, and it occurred both in PRP and in whole-blood platelet aggregation. MGDF also "primed" the release of adenosine triphosphates and the production of thromboxane B2 by platelets stimulated with ADP, EPI, and THR. When added 15 seconds after the preincubation of platelets with subthreshold concentrations of ADP, EPI, and THR, MGDF exhibited a synergism with these agonists. Moreover, we observed a "priming" effect of MGDF on the phosphorylation of p-42 mitogen-activated protein kinase promoted by ADP, EPI, and THR. These observations suggest that thrombopoietin may play a physiologic role in modulating the response of platelets to several stimuli and thereby their hemostatic potential.
Insights
Megakaryocyte growth and development factor (MGDF) primes platelets, enhancing their sensitivity to agonists like ADP and thrombin. This priming effect suggests thrombopoietin
Area of Science:
- Hematology
- Molecular Biology
- Biochemistry
Background:
- The c-Mpl receptor for thrombopoietin is present on circulating platelets.
- Megakaryocyte growth and development factor (MGDF) is a recombinant protein related to thrombopoietin.
Purpose of the Study:
- To evaluate the effect of MGDF on platelet aggregation in platelet-rich plasma (PRP) and whole blood.
- To investigate MGDF's influence on platelet activation markers and signaling pathways.
Main Methods:
- Platelet aggregation assays were performed using PRP and whole blood.
- Platelets were preincubated with MGDF before stimulation with agonists (ADP, EPI, THR).
- Platelet activation markers including ATP release, thromboxane B2 production, and p-42 MAPK phosphorylation were measured.
Main Results:
- MGDF alone did not induce platelet aggregation but 'primed' platelets to become more sensitive to agonists.
- This priming effect was dose- and time-dependent and observed in both PRP and whole blood.
- MGDF enhanced agonist-induced ATP release, thromboxane B2 production, and p-42 MAPK phosphorylation.
Conclusions:
- MGDF significantly modulates platelet responsiveness to various stimuli.
- Thrombopoietin signaling may play a physiological role in regulating platelet activation and hemostatic potential.